Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes

Rheumatology

Volumn 45, Issue 6, 2006, Pages 703-710

  Jang, C H ^a   Choi, J H ^a   Byun, M S ^a   Jue, D M ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Chloroquine; Cytokines; Gene regulation; Inflammation; Monocytes macrophages; Rheumatoid arthritis

Indexed keywords

AMMONIUM CHLORIDE; CHLOROQUINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; METHYLAMINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INHIBITION KINETICS; MACROPHAGE; MONOCYTE; NORTHERN BLOTTING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEADY STATE;

ANTIRHEUMATIC AGENTS; CELLS, CULTURED; CHLOROQUINE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MONOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745634132     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei282     Document Type: Article

References (44)

1. Ivashkiv LB. Cytokine expression and cell activation in inflammatory arthritis. Adv Immunol 1996;63:337-76.
2. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
3. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
4. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/ cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988;53:45-53.
5. Jue DM, Sherry B, Luedke C, Manogue KR, Cerami A. Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophages. Biochemistry 1990;29:8371-7.
6. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor-α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
7. Field M, Chu C, Feldmann M, Maini RN. Interleukin-6 localization in the synovial membrane in rheumatoid arthritis. Rheumatol Int 1991;11:45-50.
8. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
9. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
10. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
11. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
12. Choy EH, Isenberg DA, Garrood T et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46:3143-50.
13. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
14. HERA study group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study. Am J Med 1995; 98:156-68.
15. Ertel W, Morrison MH, Ayala A, Chaudry IH. Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prostaglandin release. Blood 1991;78:1781-8.
16. Picot S, Peyron F, Donadille A, Vuillez J-P, Barbe G, Ambroise-Thomas P. Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 1993;80:127-33.
17. Van den Borne BE, Dijkmans BA, De Rooij HH, le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-β, interleukin 6, and interferon-γ production by peripheral blood mononuclear cells. J Rheumatol 1997;24:55-60.
18. Jeong, JY, Jue DM. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 1997;158:4901-7.
19. Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol 1998;274:1058-64.
20. Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-α gene expression by a nonlysosomotropic mechanism. J Immunol 2000;165:1534-40.
21. Weber SM, Chen JM, Levitz SM. Inhibition of mitogen-activated protein kinase signaling by chloroquine. J Immunol 2002;168:5303-9.
22. Jeon KI, Jeong JY, Jue DM. Thiol-reactive metal compounds inhibit NF-κB activation by blocking IκB kinase. J Immunol 2000;164:5981-9.
23. Jeong, JY, Choi JW, Jeon KI, Jue DM. Chloroquine decreases cellsurface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology 2002;105:83-91.
24. Tsuchiya S, Kobayashi Y, Goto Y et al. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res 1982;42:1530-6.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
26. Yamamura M, Uyemura K, Deans RJ et al. Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 1991;254:277-9.
27. Shin SY, Ko J, Chang JS et al. Negative regulatory role of overexpression of PLCγ1 in the expression of early growth response 1 gene in rat 3Y1 fibroblasts. FASEB J 2002;16:1504-14.
28. Matsushima K, Taguchi M, Kovacs EJ, Young HA, Oppenheim JJ. Intracellular localization of human monocyte associated interleukin 1 (IL 1) activity and release of biologically active IL 1 from monocytes by trypsin and plasmin. J Immunol 1986;136:2883-91.
29. Seglen PO. Inhibitors of lysosomal function. Methods Enzymol 1983;96:737-64.
30. Decker T, Lohmann-Matthes ML, Gifford GE. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 1987;138:957-62.
31. Espevik T, Nissen-Meyer J. Tumour necrosis factor-like activity on paraformaldehyde-fixed monocyte monolayers. Immunology 1987;61:443-8.
32. Alexopoulou L, Pasparakis M, Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 1997; 27:2588-92.
33. Kusters S, Tiegs G, Alexopoulou L et al. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 1997;27:2870-5.
34. Solorzano CC, Ksontini R, Pruitt JH et al. Involvement of 26-kDa cell-associated TNF-α in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol 1997;158:414-9.
35. Mueller C, Corazza N, Trachsel-Loseth S et al. Noncleavable transmembrane mouse tumor necrosis factor-α (TNF-α) mediates effects distinct from those of wild-type TNF-α in vitro and in vivo. J Biol Chem 1999;274:38112-8.
36. Ruuls SR, Hoek RM, Ngo VN et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001; 15:533-43.
37. Wang P, Wu P, Wiegel MI, Egan RW, Billah MM. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 1994;153:811-6.
38. Dokter WH, Koopmans SB, Vellenga E. Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6 and NF-κB) which are involved in IL-6 regulation. Leukemia 1996;10:1308-16.
39. Maxfield FR. Weak bases and ionophores rapidly and reversibly raise the pH of endocytic vesicles in cultures mouse fibroblasts. J Cell Biol 1982;95:676-81.
40. Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A. The secretory route of the leaderless protein interleukin 1β involves exocytosis of endolysosome-related vesicles. Mol Biol Cell 1999; 10:1463-75.
41. Mackenzie AH. Pharmacologic actions of 4-aminoquinoline compounds. Am J Med 1983;75(Suppl.):5-10.
42. Miller DR, Fiechtner JJ, Carpenter JR, Brown RR, Stroshane RM, Stecher VJ. Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum 1987;30:567-71.
43. French JK, Hurst NP, O'Donnell ML, Betts WH. Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: Relation to cellular concentrations during antirheumatic therapy. Ann Rheum Dis 1987;46:42-5.
44. Isaacson D, Elgart M, Turner ML. Anti-malarials in dermatology. Int J Dermatol 1982;21:379-95.